Research programme - neurodegenerative disease therapies - MitoSense
Latest Information Update: 08 Mar 2024
At a glance
- Originator MitoSense
- Class Cell therapies
- Mechanism of Action Mitochondria replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Neurodegenerative disorders
Most Recent Events
- 25 Jan 2024 Research programme - neurodegenerative disease therapies - MitoSense is available for licensing as of 05 Feb 2024. https://www.mitosenseinc.com/ (MitoSense website; January 2024)
- 25 Jan 2024 MitoSense has patent pending for MOT™ Technology (MitoSense website; January 2024)
- 25 Jan 2024 Preclinical trials in Neurodegenerative disorders in USA (Parenteral)